Journal Club- June 2018: Semaglutide and CV Outcomes

Cardiac & Renal Outcomes with Efpeglenatide in Diabetes (AMPLITUDE-O) | NEJM | Med Journal ClubПодробнее

Journal Club January 2020: PIONEER 4 + Office & Ambulatory BP association w/ Mortality & CV outcomesПодробнее

Semaglutide and Cardiovascular Outcomes in Obesity | NEJMПодробнее

Semaglutide: From Weight Loss Fad to Protection in CADПодробнее

Researcher comment: The PIONEER 6 oral semaglutide cardiovascular outcomes study | Mansoor HusainПодробнее

Sepsis and Septic Shock: Stress Dose Steroids/The ADRENAL Trial (Journal Club-ish)Подробнее

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes preziПодробнее

Video Journal Club LS KH SemaglutideПодробнее

Friday Fellows Journal Club 03-18-2022Подробнее

Journal Club 11-20-19Подробнее

JACC: CardioOncology Virtual Journal Club | June 30, 2020Подробнее

Evidence Based Reduction of Cardiovascular & Renal Outcomes in DiabetesПодробнее

Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2) | NEJM | Med Journal ClubПодробнее

Geriatric Medicine Journal Club, March 31, 2023Подробнее

Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetesПодробнее

Journal Club: Balanced CrystalloidsПодробнее

Semaglutide and Cardiovascular RisksПодробнее